MD Anderson Cancer Center

Fresh Millions will donate Saturday proceeds to MD Anderson Cancer Center | 12/6/2019

Business News / Business Angels / Fresh Millions will donate Saturday proceeds to MD Anderson Cancer Center Fresh Millions will donate Saturday proceeds to MD Anderson Cancer Center Business Angels yesterday Experience AZ Research shows eating healthy is an important way to protect yourself from cancer. Eating the right kinds of foods not only fuels cells with nutrients needed to stay healthy, but it can also potentially prevent certain types of cancer …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Follow MD Anderson Cancer Center:    

Sun Nuclear Announces Full QADS 2020 Program & Keynote Speaker | PR Newswire | 12/4/2019

MELBOURNE, Fla. , Dec. 4, Today, Sun Nuclear Corporation released the complete program for the 12th QA & Dosimetry Symposium (QADS) , held in Orlando, Florida , February 21-22, 2020 . The keynote speaker, James Hayman , M.D., of the University of Michigan , will present “Safety is No Accident - A Physician’s Perspective on Safety in 2020 and Beyond.” This keynote address kicks off two days of practical education on advancements to Patient Safety in Radiation Oncology …

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

… key test on Tuesday when a Senate committee advanced his nomination to the full chamber on an 18-5 vote. Hahn is a cancer doctor who serves as the chief medical executive at the renowned MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director of the National Cancer Institute, serves as the agency’s acting chief. Sharpless took over that interim role after the previous FDA …

Soliton Initiates Significant Step Towards Commercialization | PR Newswire | 12/3/2019

Soliton Initiates Significant Step Towards Commercialization Engages Tailfin to Support Brand Development Effort for Limited Launch in Tattoo Removal News provided by Soliton, Inc. Dec 03, 2019, 08:00 ET HOUSTON , Dec. 3, 2019 /PRNewswire/ – Medical device innovation company Soliton, Inc. (Nasdaq: SOLY ) today announced that it has engaged Tailfin, an Atlanta based brand and marketing firm, to help develop brand strategy and marketing and sales materials to help power the …

Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting | PR Newswire | 12/3/2019

Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting News provided by Genomic Testing Cooperative Dec 03, 2019, 08:00 ET IRVINE, Calif. , Dec. 3, 2019 /PRNewswire/ – Genomic Testing Cooperative, LCA (GTC) announced that they will be presenting data on their proprietary AI-based algorithms and RNA and DNA testing at the American Association of Hematology (ASH) annual …

Senate committee advances Dr. Stephen Hahn for top FDA post | Becker’s Hospital Review | 12/3/2019

Print Email The Senate health committee on Dec. 3 voted 18-5 to advance the nomination of Stephen Hahn, MD, to the post of FDA commissioner. Dr. Hahn, who is CMO of MD Anderson Cancer Center in Houston, is a practicing radiation oncologist. He was nominated by President Donald Trump in September after the resignation of Scott Gottlieb, MD. Ned Sharpless, MD, is currently serving as acting commissioner. Dr. Hahn has …

FDA commissioner nominee Hahn advances in Senate | Modern Healthcare | 12/3/2019

Print Dr. Stephen Hahn The Senate health committee on Tuesday voted to advance President Donald Trump’s pick to run the Food and Drug Administration. All committee Republicans and several Democrats voted in favor of moving Dr. Stephen Hahn’s nomination to the Senate floor on a 18-5 vote. Hahn is currently the chief medical executive at the University of Texas MD Anderson Cancer Center. Senate health committee ranking Democrat Patty Murray …

Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH | PR Newswire | 12/2/2019

Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH News provided by Dec 02, 2019, 07:00 ET - Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8 th - - Data highlighting decreased transfusion requirements for patients treated with momelotinib directly compared to ruxolitinib to be reported in a poster at ASH - VANCOUVER , Dec. 2, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA …

1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | Business Wire | 12/2/2019

… potential to expand into other indications for B-cell malignancies.” The clinical trial is led by Dr. Nitin Jain, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center (Houston, TX) in collaboration with Dr. Richard Larson, MD, Director of the Hematologic Malignancies Clinical Research Program at the University of Chicago Medicine (Chicago, IL) and with Dr. Gail Roboz, MD, Director …

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer | Business & Finance | heraldchronicle.com | Business Wire | 12/2/2019

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Dec 2, 2019– Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, said today that Curtis L. Ruegg, Ph.D. will join the company as its new President and Chief Executive Officer and will also sit on the company’s Board of Directors. The company’s Founder and current President and Chief Executive Officer, Jeanmarie Guenot, Ph.D., will transition …

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer - Business Wire | 12/2/2019

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer December 02, 2019 09:00 AM Eastern Standard Time SOUTH SAN FRANCISCO, Calif.–( BUSINESS WIRE )–Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, said today that Curtis L. Ruegg, Ph.D. will join the company as its new President and Chief Executive Officer and will also sit on the company’s Board …

In Some Surgeries, Hypnosis Is The New General Anesthesia | 12/2/2019

… state, all Levinson could make out was the calm tenor of hypnotist Rosalinda Engle telling her to relax her jaw. In reality, Levinson was lying on the operating table in a surgical suite at MD Anderson Cancer Center while her doctor resected a tumor from her right breast — a far cry from the tranquil scene she imagined. An anesthesiologist gave her the painkillers fentanyl and novocaine to numb the site …

Postdoctoral Fellowships in Experimental Cancer Biology, Genetics and Epigenetics | Nature | 11/26/2019

Postdoctoral Fellowships in Experimental Cancer Biology, Genetics and Epigenetics The University of Texas MD Anderson Cancer Center Houston, TX, United States Posted about 2 hours 25, 2020 Postdoctoral Fellowships in Experimental Cancer Biology, Genetics and Epigenetics The University of Texas MD Anderson Cancer Center Science Park invites applications for postdoctoral fellowships in experimental cancer biology, genetics and epigenetics starting immediately. Using state-of-the-art gene-editing and functional genomics …

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma | 11/26/2019

… can be cured. Materials and methods Animals Male (6wk) C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). All procedures were conducted in accordance with the guidelines established by the U.T. MD Anderson Cancer Center Institutional Animal Care and Use Committee. Cell lines and reagents B16-F10 melanoma and B16-Ova were obtained/created and cultured as described [ 12 , 13 ]. Therapeutic antibodies CTLA-4 (9H10 [Syrian Hamster …

Determining topographical radiation dose profiles using gel nanosensors | Phys Org | 11/25/2019

… with conventional dosimeters used to measure the dose uptake of external ionizing radiation. In a new study, Karthik Pushpavanam and an interdisciplinary team of researchers in the departments of Chemical Engineering, Molecular Sciences, Banner MD Anderson Cancer Center and Arizona Veterinary Oncology in the U.S. has described a novel gel-based nanosensor. The technology allows colorimetric detection and quantification of topographical radiation dose profiles during radiotherapy. Upon exposure to ionizing …

Inaugural STAT Summit Convened 300+ Health Care Leaders | Business Wire | 11/22/2019

BOSTON–(BUSINESS WIRE)–Nov 22, 2019– On Nov. 20-21, 2019, STAT ( www.statnews.com ), a national news organization focused on finding and telling compelling stories from the frontiers of health and medicine, hosted its inaugural summit with 250 of the leading minds in the life sciences. The two-day event featured panels on drug development, innovation in health care, scientific research, and other issues. The event was underwritten by the Pharmaceutical Research …

The Hopemore Specialty Spa Opens In Neiman Marcus Downtown | PR Newswire | 11/22/2019

DALLAS , Nov. 21, The Hopemore, the first specialty spa in the Metroplex to specialize in everyday esthetics as well as services for those experiencing injury, illness or elective procedures, has opened in the sixth-floor salon area of Neiman Marcus’ Downtown Dallas flagship store. THE HOPEMORE SPECIALTY SPA OPENS IN NEIMAN MARCUS DOWNTOWN The Hopemore offers luxury facials, dermaplaning, LED light therapy and full make-up applications, as well as …

Hahn Fields Queries On Electrical Stim Devices, Molybdenum Supplies For Imaging At FDA Confirmation Hearing | 11/22/2019

Hahn Fields Queries On Electrical Stim Devices, Molybdenum Supplies For Imaging At FDA Confirmation Hearing 21 Nov 2019 Sue Darcey Executive Summary MD Anderson Cancer Center chief medical officer Stephen Hahn fielded a number of questions senators asked at his 20 November confirmation hearing to lead the US FDA. Chief among them were inquiries about his government experience level, whether he would expedite a ban on electrical stimulation devices used …

Shortage of childhood cancer drug hot topic during Senate hearing for new head of FDA | FiercePharma | 11/21/2019

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, the chief medical executive at MD Anderson Cancer Center who is expected to be confirmed as the FDA Commissioner. Hahn, a radiation oncologist, told the Senate committee that as a front-line physician, he has dealt personally with the problem of drug shortages. RELATED: Teva to produce children’s chemo drug again as …

Food and Drug Administration

The Gene Therapy Spree Rolls on With $3 Billion Astellas Deal | Fortune | 12/4/2019

… Legacy biopharma companies have been pursuing these gene therapy bolt-on acquisitions at a rapid clip—especially after several major Food and Drug Administration (FDA) approvals for pioneering (though, in some cases, controversially expensive treatments … confirmation later this year. But Dr. Stephen Hahn of the MD Anderson Cancer Center faced some tough questions over his dedication to cracking down on the vaping and e-cigarette industry during his confirmation process …

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… Food and Drug Administration, the agency responsible for combating a recent wave of underage vaping. The Senate’s health committee voted 18-5 to advance the nomination of Dr. Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among teenagers. (12/3) The New York Times: F.D.A. Nominee …

National Cancer Institute

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… health committee voted 18-5 to advance the nomination of Dr. Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he … job in April. Dr. Norman E. Sharpless, director of the National Cancer Institute, had served as acting commissioner from April to Nov. 1. Although Dr. Sharpless was endorsed by four former F.D.A. commissioners and dozens …

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director of the National Cancer Institute, serves as the agency’s acting chief. Sharpless took over that interim role after the previous FDA director, Dr. Scott Gottlieb, unexpectedly exited back in March . The lopsided 18-5 vote by the Senate’s Health, Education, Labor, and Pensions (HELP) committee likely means that Hahn will ultimately be confirmed by the entire …

Biotech

The Gene Therapy Spree Rolls on With $3 Billion Astellas Deal | Fortune | 12/4/2019

… than a half dozen times . And now, Japanese pharma giant Astellas Pharma wants to pay $3 billion to buy the biotech Audentes Therapeutics. What do all of these proposed M&As have in common? They … confirmation later this year. But Dr. Stephen Hahn of the MD Anderson Cancer Center faced some tough questions over his dedication to cracking down on the vaping and e-cigarette industry during his confirmation process …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… 2014-2019: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Most of the deals included within the report occur when a … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Precision Medicine

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Malvern Daily Record | 12/4/2019

Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients with relapsed …

Clinical Research

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong Kong University of Michigan University of Oxford University of Siena Upsher-Smith …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong Kong University of Michigan University of Oxford University of Siena Upsher-Smith …

NIH

J. Wayne Meredith, MD, FACS, MCCM, is 2019-2020 ACS President-Elect | The Bulletin | 12/4/2019

… been awarded 10 grants for various trauma research studies. He is the principal investigator for a National Institutes of Health (NIH) grant for Integrative Training in Trauma and Regenerative Medicine, as well as a joint … also is an adjunct professor of breast surgery at UT MD Anderson Cancer Center, Houston. An ACS Fellow since 1994, Dr. Newman has been an active member of the Commission on Cancer (CoC) (2001−2009), serving …

Calculating the Costs of Clinical Trials | 12/1/2019

… trial participation Of the three potential risks of participating in a clinical trial listed on the National Institutes of Health (NIH) website, two are related to the potential costs, hidden and otherwise: People who participate … a recent survey by researchers at the University of Texas MD Anderson Cancer Center. Of 105 patients who had been participating in phase I clinical trials for at least one month, half lived more than …

Genomics

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Agency Avion Pharmaceuticals Aytu BioScience Back Bay Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Agency Avion Pharmaceuticals Aytu BioScience Back Bay Scientific Bavarian Nordic Bayer Bayer Healthcare Baylor College of Medicine Beckman Coulter Beijing Genomics Institute (BGI) Besins Healthcare Bill and Melinda Gates Foundation Biocon Biomnis Biotech Inc BL … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Medicaid

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… health care providers, including federally qualified health centers that serve those who don’t have health insurance or are ineligible for Medicaid. (Kounang, 12/3) The Washington Post: Trump Administration Pushes Efforts To Wipe Out HIV Amid … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

Capitol Hill Healthcare Update | 12/2/2019

… of Dr. Stephen Hahn to lead the Food and Drug Administration (FDA). Hahn, an oncologist and chief medical executive at MD Anderson Cancer Center in Houston, faced the committee for questions in November. Senators from … to determine coverage and payment decisions, the Centers for Medicare & Medicaid Services can take the institute’s research into consideration along with other factors. Cassidy, a former practicing gastroenterologist, said healthcare costs are lowered when patients …

Patient Safety

Sun Nuclear Announces Full QADS 2020 Program & Keynote Speaker | PR Newswire | 12/4/2019

… Perspective on Safety in 2020 and Beyond.” This keynote address kicks off two days of practical education on advancements to Patient Safety in Radiation Oncology. Hosted by Sun Nuclear, QADS is focused exclusively on Quality … QA - A Medical Physicist’s Perspective” Geoffrey Ibbott , Professor Emeritus, UT MD Anderson Cancer Center, Jericho, VT “Future Directions in Patient Specific QA” Moyed Miften, Ph.D., University of Colorado School of Medicine, Aurora, CO “AAPM Initiatives …

J. Wayne Meredith, MD, FACS, MCCM, is 2019-2020 ACS President-Elect | The Bulletin | 12/4/2019

… in various capacities on the Patient Education Committee (Chair, 2004−2008; Co-Chair, 2009−2013; Consultant, 2013−2014). He also served on the Patient Safety and Quality Improvement Committee (2004−2007). Dr. Bailey is a past-president of the … also is an adjunct professor of breast surgery at UT MD Anderson Cancer Center, Houston. An ACS Fellow since 1994, Dr. Newman has been an active member of the Commission on Cancer (CoC) (2001−2009), serving …

Diagnostic Imaging

Sun Nuclear Announces Full QADS 2020 Program & Keynote Speaker | PR Newswire | 12/4/2019

… Ph.D., University of Michigan Medical Center, Ann Arbor, MI “Independent QA - A Medical Physicist’s Perspective” Geoffrey Ibbott , Professor Emeritus, UT MD Anderson Cancer Center, Jericho, VT “Future Directions in Patient Specific QA” Moyed Miften, Ph.D … Nuclear Corporation Sun Nuclear provides innovative solutions for Radiation Therapy, Diagnostic Imaging and Patient Alignment. Our mission is to enable healthier lives by improving the detection and treatment of cancer. More than 5,000 cancer centers …

Top Summer Programs High School Students Dont Want to Miss Out On | 12/4/2019

MD Anderson Cancer Center lets Texas high school seniors delve into the medical field, particularly molecular genetic technology, diagnostic imaging and radiation therapy. Students participate in workshops, learn lab techniques and attend college-level lectures. A small stipend is offered. Location: Houston, TX Cost: Living expenses, if students home is more than 20 miles away. Deadline: Early January 2017 Does this interest you? Apply here!3. Smithsonian Institution - Smithsonian Latino …

Pfizer

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Diva PDS Biotechnology Peking University Perinatal Quality Foundation PerkinElmer Perrigo Pfizer PharmaJet Pharmanest Pharma Solutions Peru Psyche Systems Radius Health Rebiotix Recipharm Reproductive Health Science Reprogenetics rEVO Biologics Roche Romark Laboratories Royal Philips Electronics Sanofi …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Diva PDS Biotechnology Peking University Perinatal Quality Foundation PerkinElmer Perrigo Pfizer PharmaJet Pharmanest Pharma Solutions Peru Psyche Systems Radius Health Rebiotix Recipharm Reproductive Health Science Reprogenetics rEVO Biologics Roche Romark Laboratories Royal Philips Electronics Sanofi …

Merck

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic Therapeutic MSD Mundipharma MyBiotics Pharma Mylan Laboratories Myovant Sciences Myrtle Potter & Company …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova MedTech For Solutions Medtronic Mel-Mont Medical MenoGeniX Merck and Co Merck KGaA Merck Serono Merus Labs International MilanaPharm Millendo Therapeutics Ministry of Health (Turkey) Mission Pharmacal Mithra Pharmaceuticals Mitsubishi Tanabe Pharma Morphic Therapeutic MSD Mundipharma MyBiotics Pharma Mylan Laboratories Myovant Sciences Myrtle Potter & Company …

Amgen

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Advaxis Adynxx AEterna Zentaris Agency for Healthcare Research and Quality Agile Therapeutics AirStrip Technologies Albion Allakos Alvogen American Dental Association Amgen Amos Gazit ANI Pharmaceuticals ApolloBio Arbor Pharmaceuticals Arc Medical Design Ascend Therapeutics ASKA Pharmaceuticals … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Advaxis Adynxx AEterna Zentaris Agency for Healthcare Research and Quality Agile Therapeutics AirStrip Technologies Albion Allakos Alvogen American Dental Association Amgen Amos Gazit ANI Pharmaceuticals ApolloBio Arbor Pharmaceuticals Arc Medical Design Ascend Therapeutics ASKA Pharmaceuticals … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Boehringer Ingelheim

Global Proteomics Partnering Terms and Agreements 2014-2019 - Deal Type, Industry Sector, Stage Of Development, Technology Type, Therapeutic Indication | The Wapakoneta Daily News | 12/4/2019

… South Dakota Axil Scientific Bayer Bellus Health Berg Bio-Techne Biocartis Biodesix Biognosys BioNova Cientifica Biotest bioVidria Bioyong BluePen Biomarkers Boehringer Ingelheim Bristol-Myers Squibb Bruker c-LEcta California Institute for Quantitative Biosciences (QB3) Cambridge … LifeArc Luxembourg Institute of Health Mariel Therapeutics Massachusetts General Hospital MD Anderson Cancer Center Medgenics Medical University of South Carolina MedImmune Memorial Sloan Kettering Cancer Center Merck and Co Metabolon Moderna Therapeutics Mologic MRM Proteomics …

Global Proteomics Partnering Terms and Agreements 2014-2019 - Deal Type, Industry Sector, Stage Of Development, Technology Type, Therapeutic Indication | Benzinga | 12/4/2019

… South Dakota Axil Scientific Bayer Bellus Health Berg Bio-Techne Biocartis Biodesix Biognosys BioNova Cientifica Biotest bioVidria Bioyong BluePen Biomarkers Boehringer Ingelheim Bristol-Myers Squibb Bruker c-LEcta California Institute for Quantitative Biosciences (QB3) Cambridge … LifeArc Luxembourg Institute of Health Mariel Therapeutics Massachusetts General Hospital MD Anderson Cancer Center Medgenics Medical University of South Carolina MedImmune Memorial Sloan Kettering Cancer Center Merck and Co Metabolon Moderna Therapeutics Mologic MRM Proteomics …

GlaxoSmithKline

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Institute for Innovation Foresee Pharmaceuticals Fougera Pharmaceuticals Fuji Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Institute for Innovation Foresee Pharmaceuticals Fougera Pharmaceuticals Fuji Pharma Genea Biomedx Genoma Genome Medical German Cancer Research Center Gilead Sciences GlaxoSmithKline GOG Foundation Golden Valley Development Good Start Genetics Grunenthal Guided Therapeutics Gynica Halt Medical … Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina Medical University South Carolina MediCare International MediGene MedikorPharma MedImmune Medinova …

Thermo Fisher

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong …

Thermo Fisher Scientific

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Globe Newswire | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong …

Global Gynecology Partnering Deal Trends, Players and Financials Directory 2019: Deals Signed Between the World’s Pharmaceutical and Biotechnology Companies | Benzinga | 12/4/2019

… Corporation of America Laccure Lake Consumer Products Lee’s Pharmaceutical LFB Biotechnologies LifeCodexx Lumara Health Lumir Lab Massachusetts General Hospital McKesson MD Anderson Cancer Center MDNA Life Sciences Meda MEDCIS Pathlabs Medical University of South Carolina … Tessa Therapeutics Teva Pharmaceutical Industries Teva Pharmaceuticals USA Theramex TherapeuticsMD Thermo Fisher Scientific Transgene Trimel Pharmaceuticals Trivector Biomed Trophogen twoXAR Unified Women’s Clinical Research University College Dublin Conway Institute University Magna Graecia University of Hong …

Purdue Pharma

Global Proteomics Partnering Terms and Agreements 2014-2019 - Deal Type, Industry Sector, Stage Of Development, Technology Type, Therapeutic Indication | The Wapakoneta Daily News | 12/4/2019

… Peptide Technologies Karolinska Institute Karolinska University Hospital KineMed Labgene Scientific LifeArc Luxembourg Institute of Health Mariel Therapeutics Massachusetts General Hospital MD Anderson Cancer Center Medgenics Medical University of South Carolina MedImmune Memorial Sloan Kettering Cancer … Bioscience Pressure BioSciences Probiodrug AG Pronutria Proteomics International Prothelia pSivida Purdue Pharma Purdue Research Foundation Purolite Reaction Biology Replicel Life Sciences rEVO Biologics Roche Saint Louis University Saromics Scienion Sciex Scripps Research Institute Selecta Biosciences …

Global Proteomics Partnering Terms and Agreements 2014-2019 - Deal Type, Industry Sector, Stage Of Development, Technology Type, Therapeutic Indication | Benzinga | 12/4/2019

… Peptide Technologies Karolinska Institute Karolinska University Hospital KineMed Labgene Scientific LifeArc Luxembourg Institute of Health Mariel Therapeutics Massachusetts General Hospital MD Anderson Cancer Center Medgenics Medical University of South Carolina MedImmune Memorial Sloan Kettering Cancer … Bioscience Pressure BioSciences Probiodrug AG Pronutria Proteomics International Prothelia pSivida Purdue Pharma Purdue Research Foundation Purolite Reaction Biology Replicel Life Sciences rEVO Biologics Roche Saint Louis University Saromics Scienion Sciex Scripps Research Institute Selecta Biosciences …

Weill Cornell Medicine

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer | Business & Finance | heraldchronicle.com | Business Wire | 12/2/2019

… MD Anderson Cancer Center, New York-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, Fred Hutchinson Cancer Research Center, The Ohio State University Wexner Medical Center, University of Pennsylvania Medical Center, Northwestern Memorial Hospital, and The Johns Hopkins Hospital. The safety, efficacy and selectivity of AMV564 was highlighted most recently at both the 24 th European Hematology Association (EHA) meeting in Amsterdam (Abstract S877) and at the 60 th …

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer - Business Wire | 12/2/2019

… MD Anderson Cancer Center, New York-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, Fred Hutchinson Cancer Research Center, The Ohio State University Wexner Medical Center, University of Pennsylvania Medical Center, Northwestern Memorial Hospital, and The Johns Hopkins Hospital. The safety, efficacy and selectivity of AMV564 was highlighted most recently at both the 24 th European Hematology Association (EHA) meeting in Amsterdam (Abstract S877) and at the 60 th …

BeiGene

The return of the megamerger | 12/2/2019

… in a deal worth $13.4 billion. Amgen pays $2.7 billion for a roughly 20% stake in the Chinese biopharma firm BeiGene. Gilead Sciences pays Galapagos $5.1 billion as part of a 10-year research pact … leadership and crisis experience: he steered the University of Texas MD Anderson Cancer Center out of financial and legal trouble, and while he was at the University of Pennsylvania, he took responsibility for shoddy treatment …

FDA Approves BeiGene’s Brukinsa to Treat Adults with Mantle Cell Lymphoma | 11/19/2019

The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene ’s Brukinsa ( zanubrutinib ) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at least one prior … the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center , and a clinical trial investigator. “Today we have a new option for our adult patients who have received one prior systemic …

SV Health Investors

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

… Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of … syndicate of life science investors from the US and Europe: SV Health Investors, New Leaf Ventures, Novo A/S and IP Group. For further information please visit: www.karustherapeutics.com Contacts Instinctif Partners Dr Christelle Kerouedan / Katie …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Malvern Daily Record | 12/4/2019

… Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of … syndicate of life science investors from the US and Europe: SV Health Investors, New Leaf Ventures, Novo A/S and IP Group. For further information please visit: www.karustherapeutics.com …

MPM Capital

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer | Business & Finance | heraldchronicle.com | Business Wire | 12/2/2019

… in a First-in-Human Phase 1 trial in patients with relapsed/refractory AML at Washington University School of Medicine, MD Anderson Cancer Center, New York-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine … C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC. For more information, please visit www.amphivena.com . View source version on businesswire.com : https://www.businesswire.com/news/home …

Amphivena Appoints Dr. Curtis L. Ruegg as President and Chief Executive Officer - Business Wire | 12/2/2019

… in a First-in-Human Phase 1 trial in patients with relapsed/refractory AML at Washington University School of Medicine, MD Anderson Cancer Center, New York-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine … C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC. For more information, please visit www.amphivena.com . Contacts …

Morgan Stanley

They have informed Ms Lion her comments about Mahatma | 11/4/2019

… German renewable energy company PNE AG , has intensified criticism of a standing takeover bid from a cheapest sominex buy shop Morgan Stanley-controlled fund, a letter seen by Reuters shows. An accused paedophile has been … Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said on Friday. Depriving people of a platform works in cheap …

Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators | Globe Newswire | 8/5/2019

… Français Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators Notable joins Amazon, Chobani, L’Oréal, Morgan Stanley, P&G, and other leading companies to top the list August 05, 2019 … been validated in multiple independent clinical studies in partnership with MD Anderson Cancer Center, University of California San Francisco, Rady Children’s Hospital, and Texas Children’s Hospital, among others. “Other titles catalog perquisites and benefits. Fast …

Goldman Sachs

Music industry version of a royal seal of approval Adele Amy | 11/3/2019

… Donald Trump atomoxetine online from canada plans to nominate Dr. Stephen Hahn, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the Food and Drug Administration, the White House said … World Cup final in Yokohama. A Texas retirement system and Goldman Sachs Group Inc pulled a combined $584 million from Fisher Investments on Friday, after allegations that firm founder Ken Fisher made biseptol online shopping …

Regional Spotlight: Metro New York, New England, and the Mid-Atlantic | 10/28/2019

… completed, is in process, or has been approved and funded and is about to begin.” National corporate leaders like the MD Anderson Cancer Center at Cooper, Campbell Soup, and Subaru, along with community, business, and … the lead developer, along with joint owners Plank Industries and Goldman Sachs Urban Investment Group. Kevin Plank, founder and chief executive officer of Under Armour, played a key role in getting development plans started but …

Industry Ventures

Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program | Globe Newswire | 10/28/2019

… HOUSTON, Oct. 28, 2019 (GLOBE NEWSWIRE) – Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP ), and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating to Ziopharm’s … Prat, Ph.D., J.D. , senior vice president for Research Administration and Industry Ventures at MD Anderson. “We are pleased to be working with Ziopharm to advance a new generation of cell therapies, and we are hopeful …

Leukemia & Lymphoma Society

TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results | Globe Newswire | 10/17/2019

… for more than 40 funded clinical research protocols and has authored more than 800 articles in peer-reviewed journals, 30 invited articles, and numerous book chapters and abstracts. After 30 years at the MD Anderson Cancer Center, she is currently the Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center, Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, and the …

Remeditex Ventures

Soliton Announces $6.25 Million Private Placement | PR Newswire | 10/10/2019

MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into definitive agreements with certain institutional and accredited investors to raise aggregate gross proceeds of approximately $6.25 million through the private placement of its equity securities. The financing was led by Remeditex Ventures, LLC, the Company’s largest shareholder, which agreed to purchase $2.0 million of the securities in the private placement. Soliton will sell 485,250 shares of the …

Soliton Announces $6.25 Million Private Placement | BioSpace | 10/10/2019

MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into definitive agreements with certain institutional and accredited investors to raise aggregate gross proceeds of approximately $6.25 million through the private placement of its equity securities. The financing was led by Remeditex Ventures, LLC, the Company’s largest shareholder, which agreed to purchase $2.0 million of the securities in the private placement. Soliton will sell 485,250 shares of the …

B Capital Group

Notable Nabs $40M to Expand Drug Discovery Platform for Personalized Oncology | HIT Consultant | 7/17/2019

… rapidly advances cancer drug development has raised $40M in Series B funding. The Series B round is co-led by B Capital Group and LifeForce Capital. LifeForce is a returning investor, joined by new investors … validated in multiple independent clinical studies conducted by Stanford University, MD Anderson Cancer Center, University of California San Francisco, Rady Children’s Hospital, and Texas Children’s Hospital, among others …

Notable Announces $40M Series B Round to Fuel Development of Its Drug Discovery Platform for Personalized Oncology | Globe Newswire | 7/16/2019

B Capital Group and LifeForce Capital Co-Lead Investment to Accelerate Notable’s Automated Lab, AI Technology, and Precision Drug Discovery July 16, 2019 07:00 ET Source: Notable Labs SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE … validated in multiple independent clinical studies conducted by Stanford University, MD Anderson Cancer Center, University of California San Francisco, Rady Children’s Hospital, and Texas Children’s Hospital, among others. “We are very impressed with the groundbreaking …

SunTrust Robinson Humphrey

Affimed N.V. (AFMD) CEO Adi Hoess on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/22/2019

… Officer Florian Fischer - Chief Financial Officer Leila Alland - Chief Medical Officer Maurice Raycroft - Jefferies Jim Birchenough - Wells Fargo Peter Lawson - SunTrust Robinson Humphrey Daina Graybosch - SVB Leerink Yale Jen - Laidlaw Company Gregory Gin Thank you … An example of these efforts is our work with the MD Anderson Cancer Center and their investigator-sponsored study directed towards development of an off-the-shelf adoptive immunotherapy comprised of AFM13 premixed with MD …

TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/11/2019

… Weiss - Executive Chairman & Chief Executive Officer Alethia Young - Cantor Fitzgerald Ren Benjamin - Raymond James Ed White - H.C. Wainwright Pete Lawson - SunTrust Robinson Humphrey Matt Kaplan - Ladenburg Thalmann Operator Greetings and welcome to the TG Therapeutics … the oral presentation given by Dr. Nathan Fowler of the MD Anderson Cancer Center at AACR annual meeting, reporting positive interim data from the MZL Cohort from the UNITY-NHL trial. Shortly after, we received …

William Blair

Pure Storage, Inc. (PSTG) CEO Charlie Giancarlo on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/22/2019

… Strategy Conference Call Participants Alex Kurtz - KeyBanc Steve Milunovich - Wolfe Research Aaron Rakers - Wells Fargo Pinjalim Bora - JPMorgan Jason Ader - William Blair Karl Ackerman - Cowen Andrew Nowinski - Piper Jaffray Katy Huberty - Morgan Stanley Rod Hall … quarter, U.K. Ministry of Defense and the University of Texas MD Anderson Cancer Center have both chosen FlashBlade, signaling excitement around our flash-to-flash-to-cloud architecture and rapid restore use case. This is …

Pure Storage, Inc. (PSTG) Q1 2019 Earnings Call Transcript - Nasdaq.com | 5/22/2019

… to gain better insight into their data. And finally, this quarter, UK Ministry of Defense and the University of Texas MD Anderson Cancer Center have both chosen FlashBlade, signaling the excitement around our flash-to … you. Operator Your next question comes from Jason Ader from William Blair. Jason Ader – William Blair – Analyst Yeah. Thank you. I got a couple, I want to slip in two. Just on – continuing on the …

MD Anderson Cancer Center, Houston TX

CAR T-cell therapy effective for relapsed mantle cell lymphoma patients | 12/10/2019

CAR T-cell therapy effective for relapsed mantle cell lymphoma patients Dec 10, 2019 0 Comments One-year study results show majority of patients who relapsed achieved complete response HOUSTON ― A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR …

University of Texas MD Anderson Cancer Center

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

… University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT . Clinicians, visit NCCN.org . Patients and caregivers, visit NCCN.org/patients . Media, visit NCCN.org/news . Follow NCCN on Twitter @NCCN , Facebook @NCCNorg , and Instagram @NCCNorg . Media Contact: Rachel Darwin 267-622-6624 [email protected] SOURCE National Comprehensive Cancer Network Related Links …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

The University of Texas MD Anderson Cancer Center

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

… The University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT . Clinicians, visit NCCN.org . Patients and caregivers, visit NCCN.org/patients . Media, visit NCCN.org/news . Follow NCCN on Twitter @NCCN , Facebook @NCCNorg , and Instagram @NCCNorg . Media Contact: Rachel Darwin 267-622-6624 [email protected] SOURCE National Comprehensive Cancer Network Related …

Karus Therapeutics to Announce Positive New Data from Phase I Relapsed/Refractory B-Cell Lymphoma Trial at ASH | Business Wire | 12/4/2019

OXFORDSHIRE, England- Karus Therapeutics Ltd (‘Karus’), a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019. The Phase I clinical trial, conducted at The University of Texas MD Anderson Cancer Center, has examined the safety, tolerability, pharmacokinetic properties and pharmacodynamic effects of KA2237 in patients …

Mayo Clinic

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

… Kimmel Comprehensive Cancer Center at Johns Hopkins , Baltimore, MD ; Robert H. Lurie Comprehensive Cancer Center of Northwestern University , Chicago, IL ; Mayo Clinic Cancer Center, Phoenix / Scottsdale, AZ , Jacksonville, FL , and Rochester, MN ; Memorial Sloan Kettering … Rogel Cancer Center, Ann Arbor, MI ; The University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow …

Massachusetts General Hospital

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

… Taussig Cancer Institute, Cleveland, OH ; City of Hope National Medical Center, Duarte, CA ; Dana - Farber /Brigham and Women’s Cancer Center Massachusetts General Hospital Cancer Center, Boston, MA ; Duke Cancer Institute, Durham, NC ; Fox Chase Cancer … Rogel Cancer Center, Ann Arbor, MI ; The University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow …

Cleveland Clinic

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

… Pennsylvania , Philadelphia, PA ; Fred & Pamela Buffett Cancer Center, Omaha, NE ; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH ; City of Hope National Medical Center, Duarte, CA … Rogel Cancer Center, Ann Arbor, MI ; The University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow …

UT Southwestern Medical Center

J. Wayne Meredith, MD, FACS, MCCM, is 2019-2020 ACS President-Elect | The Bulletin | 12/4/2019

… Association, the Texas Surgical Society, and the Society of American Gastrointestinal Endoscopic Surgeons. He earned his medical degree from the UT Southwestern Medical Center, Dallas; completed his internship at Parkland Memorial Hospital, Dallas; completed his … also is an adjunct professor of breast surgery at UT MD Anderson Cancer Center, Houston. An ACS Fellow since 1994, Dr. Newman has been an active member of the Commission on Cancer (CoC) (2001−2009), serving …

Father with rare cancer caught in the middle of insurance showdown between Cigna and Southwestern Health Resources | 12/3/2019

… a letter from Cigna saying that he may not be covered when he goes in for a cancer scan at UT Southwestern Medical Center next month. Michael Orpen and his wife Kelli. Orpen Family Orpen … eyes. Worst case scenario, Orpen would have to travel to MD Anderson Cancer Center in Houston for his scans. The drive is around 4 hours on a good day. Orpen would still have access to …

UPMC

Sun Nuclear Announces Full QADS 2020 Program & Keynote Speaker | PR Newswire | 12/4/2019

… MD Anderson Cancer Center, Jericho, VT “Future Directions in Patient Specific QA” Moyed Miften, Ph.D., University of Colorado School of Medicine, Aurora, CO “AAPM Initiatives and Emergent RT Technologies” Saiful Huq , Ph.D., UPMC Hillman Cancer Center, Pittsburgh, PA “QADS attendees routinely praise the high quality of presentations at this event,” notes Jeff Simon , CEO of Sun Nuclear. “We are proud to offer this highly valuable and practical symposium for Medical …

Pieris Pharmaceuticals to Host R&D Event | 11/7/2019

MD Anderson Cancer Center Geoffrey Y. Ku, MD, Assistant Attending Physician and Head, Esophagogastric Section, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Anuradha Ray, PhD, Professor of Medicine, Department of Immunology and UPMC Endowed Chair in Lung Immunology Medicine, University of Pittsburgh Sally E. Wenzel, MD, Professor of Medicine, Department of Medicine; Chair, Department of Occupational & Environmental Health; Acting Director, Asthma Environmental Lung Health Institute and UPMC Endowed …

Houston Methodist

Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting | PR Newswire | 12/3/2019

… 2891-Title: “Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning” Collaborators: University of Texas MD Anderson Cancer Center, Houston, TX ; University of California, Irvine , CA; University Hospital Basel, Basel … Marqués De Valdecilla, Santander, Spain ; University Hospital Nijmegen, Nijmegen, NLD; Houston Methodist Hospital, Houston, TX ; Lerner Research Institute, Cleveland Clinic, Cleveland, OH . 2) 2730-Title: “Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild …

Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma | 11/21/2019

… MD Anderson Cancer Center. Cells were cultured in RPMI 1640, supplemented with 20% FBS (except for RC, DHL4, and Toledo, supplemented with 10% FBS), and 1% penicillin/streptomycin in a 5% CO2 humidified incubator. ABT199 (venetoclax) was obtained from Houston Methodist Pharmacy. KPT8602 and KPT330 were purchased from Selleckchem. Carfilzomib was purchased from Cayman Chemical. IC50 determination Cells were plated at 2 × 10 4 cells in 100-μl culture medium …

Columbia University Medical Center

Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting | PR Newswire | 12/3/2019

… MD Anderson Cancer Center, Houston, TX ; University of California, Irvine , CA; University Hospital Basel, Basel, Switzerland ; University of Verona , Verona , Italy ; Columbia University Medical Center, New York, NY ; Aalborg University Hospital, Aalborg, Denmark ; Well Cornell Medical College, New York, NY ; Cleveland Clinic, Cleveland, OH ; San Raffaele Scientific Institute, Milano, Italy ; San Raffaele Hospital, Milan, Italy ; Odense University Hospital, Odense, Denmark ; Instituto de Investigación Marqués De Valdecilla, Santander, Spain ; University Hospital …

FDA rotating commissioner’s chair finds new nominee, former national coordinator joins Google, and more digital health hires and departures | MobiHealthNews | 11/5/2019

… acting commissioner of the FDA, with President Donald Trump pointing to Dr. Stephen Hahn , currently the chief medical officer of MD Anderson Cancer Center, as his official appointment for the role on Friday. Assistant Secretary … strategy and policy for Verily Life Sciences and Google Health. … Columbia University Medical Center Assistant Professor of Cardiology Dr. David Tsay is the latest to rein his horse to Apple’s healthcare wagon, CNBC reports . Tsay …

Cigna

Father with rare cancer caught in the middle of insurance showdown between Cigna and Southwestern Health Resources | 12/3/2019

… that may force him to drive four hours to receive adequate treatment in Houston. That all can be avoided if Cigna and Southwestern Health Resources come to an agreement over insurance rates before Jan. 1 … eyes. Worst case scenario, Orpen would have to travel to MD Anderson Cancer Center in Houston for his scans. The drive is around 4 hours on a good day. Orpen would still have access to …

Calculating the Costs of Clinical Trials | 12/1/2019

… applicable plan limitations for coverage of out-of-network care will apply to routine care costs in clinical trials.” 6 Cigna’s clinical trial fact sheet notes that routine patient services, such as transplant-related services … a recent survey by researchers at the University of Texas MD Anderson Cancer Center. Of 105 patients who had been participating in phase I clinical trials for at least one month, half lived more than …

Aetna

Wednesday, November 20, 2019 | Kaiser Health News | 11/20/2019

… from mysterious vaping illnesses to the promise of gene therapies. Hahn, who currently serves as the chief medical executive of MD Anderson Cancer Center, is auditioning for the FDA’s top job at a transformational time … Making Progress Though its Medicaid contract is still at stake, Aetna Better Health is making progress, Kansas lawmakers and state regulators said this week. …State regulators had put Aetna on notice in July that it …

Long Island orthopedic practice leaves health system, joins management group | Crain’s New York Business | 11/4/2019

MD Anderson Cancer Center in Houston. He has never worked in government. HAVEN HEALTHCARE: Amazon and JPMorgan Chase are offering new insurance plans to their employees as part of Haven Healthcare, their joint venture with Berkshire Hathaway. The Haven plan has no deductible and offers wellness incentives, such as keeping blood pressure below certain levels, Bloomberg reported . The products, which are administered by Aetna and Cigna, are being offered to …

Health Net

Internationally Recognized UPMC Cancer Surgeon Joins Allegheny Health Network as Cancer Institute Chair | PRWeb | 11/6/2019

Internationally Recognized UPMC Cancer Surgeon Joins Allegheny Health Network as Cancer Institute Chair Share Article David L. Bartlett, MD, an internationally recognized cancer researcher and a pioneer in the use of highly advanced surgical therapies … Center in New York. He also performed clinical research at MD Anderson Cancer Center in Houston. Dr. Bartlett specializes in all aspects of surgical oncology, with expertise in peritoneal surface malignancies, the management of complex …

Humana

7 can’t-miss panels at HLTH19 | Healthcare Dive | 10/24/2019

… Rx ), Jay Bhatt, SVP and chief medical officer of the American Hospital Association, and Rebecca Kaul, VP and CIO of MD Anderson Cancer Center. Intermountain recently started a new company that consults with payers and … health and benefits company Accolade, which works with companies like Humana, Independence Blue Cross, Teladoc and Lowes on improving health outcomes …

Global Genitourinary Partnering Deal Trends, Players and Financials Directory 2014-2019 | PR Newswire | 10/24/2019

… of Canada Hainan Sihuan Pharmaceutical Hancock Jaffe Laboratories Harvard Stem Cell Institute Healthy.io Helix BioPharma HemoCleanse Hitachi Medical Systems Europe Humana Hydra Biosciences HydroCision Icahn School of Medicine at Mount Sinai Idera Pharmaceuticals IDIBELL ImpediMed … Mar Cor Purification Mariel Therapeutics Massachusetts General Hospital Mayo Clinic MD Anderson Cancer Center MedCom MediBeacon MediGene Medinova Medipal Holdings Medison Pharma Medline Industries Medpace Medtronic Meiji Seika Melinta Therapeutics Memorial Sloan Kettering Cancer Center …

UnitedHealthcare

Judge rips insurance company for ‘immoral, barbaric’ cancer denials - CNN | 5/16/2019

CNN) A federal judge blasted UnitedHealthcare last month for its “immoral and barbaric” denials of treatment for cancer patients. He made the comments in recusing himself from hearing a class-action lawsuit because of his … UnitedHealthcare refused to pay for his proton beam radiation from MD Anderson Cancer Center. “Only upon threat of litigation did UnitedHealthcare agree to reimburse him,” Scola wrote. In scathing ruling, judge rips insurer for putting …

Donald Trump

FDA Nominee Advances Through Committee, But Concerns Over How He’d Handle Vaping Epidemic Linger | Kaiser Health News | 12/4/2019

Dr. Stephen Hahn is a noted oncologist from Texas and was nominated by President Donald Trump to replace former FDA Chief Scott Gottlieb. He would be stepping into the job as the F.D.A. is confronting … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

Senate Health Committee Approves Trump’s Nominee To Lead FDA - Vaporizer Stocks | 12/4/2019

The Food and Drug Administration is getting closer to welcoming a new commissioner, as a Senate panel voted Tuesday to advance the nomination of Dr. Stephen Hahn. The U.S. Senate Committee on Health, Education, Labor & Pensions voted 18-5 to push Hahn’s nomination ahead to a full Senate vote. Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston, was nominated by President Donald Trump to …

Scott Gottlieb

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among teenagers. (12/3) The New York Times: F.D.A. Nominee Clears Senate Panel Dr. Hahn, chief medical executive at the University of Texas M.D. Anderson Cancer Center, was nominated by President Trump last month to replace Dr. Scott Gottlieb, who left the job in April. Dr. Norman …

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director of the National Cancer Institute, serves as the agency’s acting chief. Sharpless took over that interim role after the previous FDA director, Dr. Scott Gottlieb, unexpectedly exited back in March . The lopsided 18-5 vote by the Senate’s Health, Education, Labor, and Pensions (HELP) committee likely means that Hahn will ultimately be confirmed by the entire …

Ned Sharpless

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

Dr. Stephen Hahn, President Donald Trump’s nominee to be the next commissioner of the Food and Drug Administration (FDA), passed a key test on Tuesday when a Senate committee advanced his nomination to the full chamber on an 18-5 vote. Hahn is a cancer doctor who serves as the chief medical executive at the renowned MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director …

Trump’s New FDA Commissioner Nominee Advances in Senate | 12/4/2019

Ned Sharpless who has led the FDA since Gottlieb’s departure in April. Hahn is a well-known cancer doctor who currently serves as chief medical executive at the MD Anderson Cancer Center in Texas. In an 18-5 vote in the Senate Health, Education, Labor and Pensions (HELP) committee, Hahn’s nomination was advanced and sets him up to face a full chamber vote. An issue that hung over Hahn’s vote, however …

Patty Murray

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… health committee voted 18-5 to advance the nomination of Dr. Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he … Health Committee Approves Stephen Hahn As Next FDA Head Sen. Patty Murray (D-Wash.), the panel’s ranking Democrat, voted against Hahn, saying during his confirmation hearing last month he had “refused to commit to implementing …

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

… chamber on an 18-5 vote. Hahn is a cancer doctor who serves as the chief medical executive at the renowned MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director … nominee regardless. The Senate HELP committee’s ranking Democrat, Washington’s Sen. Patty Murray, did not vote for Hahn, citing the possibility that he wouldn’t back aggressive vaping and e-cigarette regulation. The political dynamics are complex …

Fred Hutchinson

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

… Durham, NC ; Fox Chase Cancer Center, Philadelphia, PA ; Huntsman Cancer Institute at the University of Utah , Salt Lake City, UT ; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA ; The Sidney Kimmel Comprehensive … Rogel Cancer Center, Ann Arbor, MI ; The University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow …

Mitt Romney

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

… chamber on an 18-5 vote. Hahn is a cancer doctor who serves as the chief medical executive at the renowned MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director … who ultimately voted to advance Hahn’s nomination is Republican Sen. Mitt Romney of Utah. In November, Romney had brought attention to the Trump administration’s seeming retrenchment on stringent, anti-vaping rules for flavored e-cigarette …

FDA Nominee Advances Through Committee, But Concerns Over How He’d Handle Vaping Epidemic Linger | Kaiser Health News | 12/4/2019

… is confronting several crises, among them, the continuing outbreak of vaping-related lung diseases. Sens. Patty Murray (D-Wash.) and Mitt Romney (R-Utah) both aired concerns during the vote about Hahn’s commitment to tackling … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

Lamar Alexander

Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on Vaping | Fortune | 12/4/2019

… chamber on an 18-5 vote. Hahn is a cancer doctor who serves as the chief medical executive at the renowned MD Anderson Cancer Center in Texas. Currently, another oncologist, Dr. Ned Sharpless, the former director … the entire Senate—a goal that HELP committee chairman Sen. Lamar Alexander, a Tennessee Republican, said he hopes to achieve by the end of the year. But critics have pointed to the hot-button issue …

Senate Health Committee Approves Trump’s Nominee To Lead FDA - Vaporizer Stocks | 12/4/2019

MD Anderson Cancer Center in Houston, was nominated by President Donald Trump to lead the FDA last month. With Republicans holding the majority in the Senate, Hahn will almost certainly sail through, but a full Senate vote has yet to be scheduled. The New York Times reported that Tennessee Sen. Lamar Alexander, the chairman of the health committee, is hopeful that a vote will be held by the end of …

Helen Diller

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine | PR Newswire | 12/4/2019

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA ; University of Colorado Cancer Center, Aurora, CO ; University of Michigan Rogel Cancer Center, Ann Arbor, MI ; The University of Texas MD Anderson Cancer Center, Houston, TX ; University of Wisconsin Carbone Cancer Center, Madison, WI ; Vanderbilt-Ingram Cancer Center, Nashville, TN ; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT . Clinicians, visit NCCN.org . Patients and caregivers, visit NCCN.org/patients . Media, visit …

Elizabeth Warren

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… Press: Biden Steps Up Hits On Buttigieg, Warren Over Health Care Joe Biden is taking aim at Pete Buttigieg and Elizabeth Warren during an eight-day tour of Iowa that the former vice president hopes … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

US Regulatory Roundup, November 2019: EtO Woes Concern Industry; FDA Pushes Back Deadline For Blended QSR/ISO 13485 Rule; And More | 12/3/2019

Elizabeth Warren of Massachusetts and Patty Murray of Washington State – sent a letter to FDA officials that raises new concerns about the agency’s legislative plan for a conditional progressive approval pathway for devices; President Trump nominated MD Anderson Cancer Center oncologist Stephen Hahn to be the next FDA commissioner; and Zimmer Biomet announced a high-risk class I recall of its ROSA Brain 3.0 robotic surgery system. The 10 most …

Bernie Sanders

First Edition: December 4, 2019 | Kaiser Health News | 12/4/2019

… former health insurance executive offered praise on Tuesday for “Medicare for All” plans put forth by Democratic presidential candidates Sens. Bernie Sanders (I-Vt.) and Elizabeth Warren (D-Mass.). Wendall Potter, who spent 20 years … Stephen Hahn, a cancer specialist and medical executive at the MD Anderson Cancer Center in Houston. Several Democrats opposed Hahn for the role, worrying he would not be tough enough tackling the vaping problem among …

Senate committee advances Dr. Stephen Hahn for top FDA post | Becker’s Hospital Review | 12/3/2019

… to advance the nomination of Stephen Hahn, MD, to the post of FDA commissioner. Dr. Hahn, who is CMO of MD Anderson Cancer Center in Houston, is a practicing radiation oncologist. He was nominated by … of Dr. Hahn were all Democrats: Patty Murray of Washington, Bernie Sanders of Vermont, Elizabeth Warren of Massachusetts, Maggie Hassan of New Hampshire and Tina Smith of Minnesota …